3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia
3
Burkitt Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Recurrence
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Biphenotypic, Acute
1
Dendritic Cell Sarcoma, Interdigitating
1
Cardiotoxicity
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Interventions
Doxorubicin
11
Razoxane
5
Dexrazoxane
5
Electrocardiography
4
Echocardiography
4
Cyclophosphamide
4
Vincristine
3
Trastuzumab
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Exercise
3
Etoposide
3
Carvedilol
3
Radiotherapy
2
Prednisone
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
Bleomycin
2
salicylhydroxamic acid
1
oblimersen
1
hydrocortisone hemisuccinate
1
dapagliflozin
1
Vascular Stiffness
1
VAP-cyclo protocol
1
Tablets
1
Silymarin
1
Reverse Transcriptase Polymerase Chain Reaction
1
Resistance Training
1
Pulse Wave Analysis
1
Palliative Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cardiotoxicity
×
hydrocortisone hemisuccinate
×
Clear all
NCT01230983
2013-06-06
T-Cell #4
Children's Oncology Group
Phase 3
Completed
573 enrolled